Search research articles
Contact Us
Filters
Showing results (151-160 of 187) with videos related to
Page
of 19
Sort By:
Cancer
|
August 21, 2025
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib
Francesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, et al.
Annals of Hematology
|
December 6, 2018
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib
Massimo Breccia, Daniela Bartoletti, Massimiliano Bonifacio, et al.
Blood Cancer Journal
|
June 9, 2018
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B<sub>2</sub> assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
Valerio De Stefano, Bianca Rocca, Alberto Tosetto, et al.
Cancer
|
February 13, 2026
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis
Francesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
March 10, 2018
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project
Francesca Palandri, Giulia Benevolo, Alessandra Iurlo, et al.
Blood
|
June 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis
Naveen Pemmaraju, Adam J Mead, Tim C P Somervaille, et al.
Cancer
|
April 1, 2022
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis
Francesca Palandri, Daniela Bartoletti, Alessandra Iurlo, et al.
British Journal of Haematology
|
August 26, 2025
Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study
Elisa Lucchini, Nicola Vianelli, Ugo Consoli, et al.
Nature
|
November 26, 2020
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms
Ashok Kumar Jayavelu, Tina M Schnöder, Florian Perner, et al.
Leukemia
|
August 30, 2022
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
Barbara Mora, Paola Guglielmelli, Andrew Kuykendall, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 187) with videos related to
Sort By:
Page
of 19
Cancer
|
August 21, 2025
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib
Francesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, et al.
Annals of Hematology
|
December 6, 2018
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib
Massimo Breccia, Daniela Bartoletti, Massimiliano Bonifacio, et al.
Blood Cancer Journal
|
June 9, 2018
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B<sub>2</sub> assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
Valerio De Stefano, Bianca Rocca, Alberto Tosetto, et al.
Cancer
|
February 13, 2026
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis
Francesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
March 10, 2018
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project
Francesca Palandri, Giulia Benevolo, Alessandra Iurlo, et al.
Blood
|
June 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis
Naveen Pemmaraju, Adam J Mead, Tim C P Somervaille, et al.
Cancer
|
April 1, 2022
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis
Francesca Palandri, Daniela Bartoletti, Alessandra Iurlo, et al.
British Journal of Haematology
|
August 26, 2025
Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study
Elisa Lucchini, Nicola Vianelli, Ugo Consoli, et al.
Nature
|
November 26, 2020
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms
Ashok Kumar Jayavelu, Tina M Schnöder, Florian Perner, et al.
Leukemia
|
August 30, 2022
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
Barbara Mora, Paola Guglielmelli, Andrew Kuykendall, et al.
Page
of 19